Evidence map›Paper›PMID 38685787›Full record

ArticleCurrent stem cell research & therapy2025

Albiflorin Inhibits Advanced Glycation End Products-Induced ROS and MMP-1 Expression in Gingival Fibroblasts.

Linlin Gao, Wenqi Fu, Yanyan Liu, Lili Fan, Shiwei Liu, Nan Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Current stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linlin GaoDepartment of Endocrinology, Endocrine and Metabolic Diseases Key Laboratory of Shanxi Province, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.
Wenqi FuDepartment of Oral Pathology, School of Dentistry, Chonnam National University, Gwangju, 61186, Republic of Korea.
Yanyan LiuDepartment of Stomatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.
Lili FanDepartment of Stomatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.
Shiwei LiuDepartment of Endocrinology, Endocrine and Metabolic Diseases Key Laboratory of Shanxi Province, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.
Nan ZhangDepartment of Stomatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, China.

Funding

Basic Scientific Research Funding of the Science and Technology Commission of Shanxi Province 202103021224359Fund for Endocrine and Metabolic Diseases Key Laboratory of Shanxi Province 202104010910009
6 · The paper itself

Abstract

backgroundPeriodontitis is a common complication of diabetes, with advanced glycation end products (AGEs) playing a key role in its pathogenesis. Albiflorin, a monoterpene glycoside, has shown potential anti-inflammatory and antioxidant properties. This study aims to investigate the effects of albiflorin on AGEs-induced gingival fibroblasts and its underlying mechanisms.

objectiveThis study aimed to evaluate the role of albiflorin in mitigating ROS production, inflammation, and MMP-1 expression in AGEs-induced gingival fibroblasts.

methodsThe viability of gingival fibroblasts treated with albiflorin and AGEs was assessed using CCK-8 assays. ROS levels were measured by DCF staining, and the expression of inflammatory markers and MMP-1 was evaluated by ELISA and qPCR. The involvement of the NF-κB and Nrf2 pathways was examined by immunoblotting.

resultsAlbiflorin enhanced the viability of AGEs-induced gingival fibroblasts and reduced ROS production. It also decreased the expression of IL-6, IL-8, RAGE, and MMP-1, suggesting an anti- inflammatory effect. Mechanistically, albiflorin modulated the NF-κB and Nrf2 pathways in AGEs-induced gingival fibroblasts.

conclusionAlbiflorin exhibited protective effects against AGEs-induced oxidative stress and inflammation in gingival fibroblasts, highlighting its potential as a therapeutic agent for periodontitis in diabetic patients. The modulation of the NF-κB and Nrf2 pathways by albiflorin provides insight into its mechanism of action.

Indexed as

FibroblastsGingivaGlycation End Products, AdvancedMatrix Metalloproteinase 1Reactive Oxygen SpeciesBridged-Ring CompoundsCells, CulturedCell SurvivalGlycosidesHumansNF-E2-Related Factor 2NF-kappa BPeriodontitisReceptor for Advanced Glycation End ProductsalbiflorinBridged-Ring CompoundsGlycation End Products, AdvancedGlycosidesMatrix Metalloproteinase 1MMP1 protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa BReactive Oxygen SpeciesReceptor for Advanced Glycation End Productsadvanced glycation end products (AGEs)albiflorinGingival fibroblastNF-κBNrf2.ROS

Identifiers

PMID38685787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.